The importance of treating by histological subtype in advanced soft tissue sarcoma (Q30240223)

12 June 2017

1 reference

title

The importance of treating by histological subtype in advanced soft tissue sarcoma (English)

1 reference

12 June 2017

2

Axel Le Cesne

0 references

author name string

Javier Martín Broto

series ordinal

1

1 reference

12 June 2017

Peter Reichardt

series ordinal

3

1 reference

12 June 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

12 June 2017

1 reference

12 June 2017

volume

13

1 reference

12 June 2017

issue

1s

1 reference

12 June 2017

page(s)

23-31

1 reference

Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions.

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Soft tissue sarcomas, a look into the future: different treatments for different subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Trabectedin clinical cases: use according to indication in diverse clinical scenarios

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Current management options for liposarcoma and challenges for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Synovial sarcoma diagnosis and management in the era of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Pazopanib: in advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0500

21 January 2018

Identifiers

DOI

10.2217/FON-2016-0500

1 reference

12 June 2017

1 reference